 |
|
|
|
|
|
WHAT TO EXPECT FROM THE 2024 ASCO GENITOURINARY CANCERS SYMPOSIUM
|
|
|
|
|
Thursday, January 25, 2024
|
|
| Oral Abstract Session A: Prostate Cancer - 11:15 AM - 12:19 PM EST |
|
|
|
|
LBA259: Long-Term Results of Dose Escalation (80 vs 70 Gy) Combined with Long-Term Androgen Deprivation in High-Risk Prostate Cancers: GETUG-AFU 18 Randomized Trial
Presented By: Christophe Hennequin, MD, Ph.D.
|
|
|
|
|
| Treatment Intensification: What To Do for Patients With Early Castration-Resistant Prostate Cancer Who Have Received Doublet or Triplet Therapy - 1:20 - 2:00 PM EST
|
|
|
|
|
PSMA-Targeting and Radium-223
Presented By: Alan Bryce, MD
|
|
|
|
|
| Poster Session A: Prostate Cancer - 2:30 PM EST
|
|
|
|
|
Abstract 27: Impact of Race on Outcomes to 177Lu-PSMA-617 (LuPSMA) for Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Presented By: Avina Rami
|
|
|
|
|
Abstract 47: Prognostic Value of Artificial Intelligence (AI) –Driven Tumor Estimation of PSMA PET Total Tumor Burden (TTB) in Newly Diagnosed High-Volume Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Francisco Osvaldo Garcia-Perez
|
|
|
|
|
Abstract 66: Underutilization of Androgen Deprivation Therapy (ADT) Intensification for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Systematic Review of Real-World Database Studies
Presented By: Amit Raval, Ph.D.
Abstract 78: Clinical Outcomes with Systemic Therapy Given After Progression on Prostate Specific Membrane Antigen Radioligand Therapy (PSMA-RLT) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Soumaya Labidi, MD
|
|
|
|
|
|
|
|
Abstract 131: Intensification of ADT with Enzalutamide in High-Risk Patients with Biochemical Relapse Following Radical Prostatectomy Undergoing Salvage Radiation: Initial Results from RTOG 3506 (STEEL)
Presented By: Edwin Melencio Posadas, MD, FACP
|
|
|
|
|
Abstract 159: MK-5684 (ODM-208), a CYP11A1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with and Without AR-LBD Mutations: CYPIDES Phase 2 Results
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
Abstract 166: Overall Survival with Darolutamide vs Placebo in Combination with Androgen-Deprivation Therapy (ADT) and Docetaxel: A Sensitivity Analysis from ARASENS Accounting for Subsequent Therapy
Presented By: Neal D. Shore, MD, FACS
|
|
|
|
|
Abstract 264: Prostate Cancer Foundation (PCF) Screening Guidelines for Prostate Cancer in Black Men in the United States
Presented By: Isla Garraway, MD, Ph.D.
|
|
|
|
|
| Trials in Progress Poster Session A: Prostate Cancer - 2:30 PM EST
|
|
|
|
|
TPS232: EORTC GUCG 2238 De-Escalate: A Pragmatic Trial to Revisit Intermittent Androgen-Deprivation Therapy in Metastatic Hormone-Naïve Prostate Cancer in the Era of New AR Pathway Inhibitors
Presented By: Guillaume Grisay, MD
|
|
|
|
|
TPS243: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing Darolutamide vs Enzalutamide Monotherapy on Serum Testosterone Levels in Patients with Castration-Sensitive Prostate Cancer After Biochemical Recurrence
Presented By: Andrew Leonard Laccetti, MD, MS
TPS247: COMBAT: A Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPr-Expressing Metastatic Castrate-Resistant Prostate Cancer
Presented By: Luke T. Nordquist, MD
|
|
|
|
|
|
|
|
TPS254: Darolutamide plus Androgen-Deprivation Therapy (ADT) in Patients with High-Risk Biochemical Recurrence (BCR) of Prostate Cancer: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ARASTEP)
Presented By: Alex Chehrazi-Raffle, MD
|
|
|
|
|
| Rapid Oral Abstract Session A: Prostate Cancer - 7:15 - 7:40 PM EST
|
|
|
|
|
Abstract 21: Differences in Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer (PCa) Based on Site of Metastasis (Mets)
Presented By: Umang Swami, MD, MS
|
|
|
|
|
|
|
| Rapid Oral Abstract Session B: Urothelial Carcinoma - 10:45 - 11:20 AM EST |
|
|
|
|
Abstract 537: Outcomes in Patients with Advanced Urothelial Carcinoma (aUC) Treated with Enfortumab Vedotin After Switch Maintenance Avelumab in the UNITE Study
Presented By: Amanda Nizam, MD
|
|
|
|
|
Abstract 540: FGFR3 Mutated (FGFR3mut+) Urothelial Carcinoma of Bladder (UCB) or Upper Tract (UTUC): A Comparative Genomic Landscape Study
Presented By: Michael Basin, MD
|
|
|
|
|
Abstract 632: Oral APL-1202 in Combination with Tislelizumab as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (MIBC): Interim Analysis of ANTICIPATE Phase II Trial
Presented By: Matt Galsky, MD, FASCO
|
|
|
|
|
| Keynote: Urothelial Carcinoma - 12:45 - 1:15 PM EST
|
|
|
|
|
Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials
Presented By: Cheryl T. Lee, MD
|
|
|
|
|
| Poster Session B: Urothelial Carcinoma - 2:30 PM EST |
|
|
|
|
Abstract 676: Urine-Based Testing for Patient Selection and Genomic Characterization of Patients with FGFR Alteration-Positive Non–muscle-Invasive Bladder Cancer (NMIBC) Treated with TAR-210
Presented By: Roger Li, MD
|
|
|
|
|
| Trials in Progress Poster Session B: Urothelial Carcinoma - 2:30 PM EST |
|
|
|
|
TPS705: ABLE-41: Nadofaragene Firadenovec-Vncg Early Use and Outcomes in a Real-World Setting in the United States
Presented By: Siamak Daneshmand, MD
TPS714: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib (CABO) and Avelumab (Av) vs Av After First-Line Platinum-Based Chemotherapy in Patients (Pts) with Metastatic Urothelial Cancer (mUC; Alliance A032001)
Presented By: Shilpa Gupta, MD
|
|
|
|
|
|
|
|
TPS722: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin (BCG) with or Without Pembrolizumab for High-Risk (HR) Non–muscle-Invasive Bladder Cancer (NMIBC) That Persists/recurs After BCG Induction
Presented By: Neal D. Shore, MD, FACS
|
|
|
|
|
| The Shortage of Drugs for Urothelial Carcinoma: Why We Can’t Get What Our Patients Need and What We Can Do About This - 4:00 - 5:00 PM EST |
|
|
|
|
Bacillus Calmette-Guerin Shortage: What’s on the Horizon to Replace?
Presented By: Joshua J Meeks, MD, Ph.D.
|
|
|
|
|
| Oral Abstract Session B: Urothelial Carcinoma - 7:15 PM EST |
|
|
|
|
LBA530: Enfortumab Vedotin (EV) in Combination with Pembrolizumab (P) Versus Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC): Subgroup Analyses Results from EV-302, a Phase 3 Global Study
Presented By: Michiel Van Der Heijden, MD, Ph.D.
|
|
|
|
|
LBA531: AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIUC) vs Observation
Presented By: Andrea B. Apolo, MD
|
|
|
|
|
Abstract 533: Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression
Presented By: Bishoy Faltas, MD
|
|
|
|
|
|
Saturday, January 27, 2024
|
|
| Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers - 10:00 AM EST
|
|
|
|
|
Abstract 425: The Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era of Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis of 2319 Patients
Presented By: Dimitrios Makrakis, MD
|
|
|
|
|
| Oral Abstract Session C: Renal and Rare Tumors - 11:15 AM - 12:30 PM EST
|
|
|
|
|
LBA359: Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab Versus Placebo for the Treatment of Clear Cell Renal Cell Carcinoma (ccRCC)
Presented By: Toni K. Choueiri, MD, FASCO
|
|
|
|
|
LBA360: Subcutaneous Nivolumab vs Intravenous Nivolumab in Patients with Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Pharmacokinetics, Efficacy, and Safety Results from CheckMate 67T
Presented By: Saby George, MD, FACP
|
|
|
|
|
| Rapid Oral Abstract Session C: Renal Cell, Adrenal, and Testicular Cancers - 4:00 - 4:40 PM EST |
|
|
|
|
Abstract 362: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma: Results from 55-Month Follow-up of the CheckMate 9ER Trial
Presented By: Maria Teresa Bourlon, MD, MSc
|
|
|
|
|
Abstract 363: Nivolumab plus Ipilimumab vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-up Data from the Phase 3 CheckMate 214 Trial
Presented By: Nizar M. Tannir, MD, FACP
|
|
|
|
|
| Incorporating Radiation Therapy, Theranostics, and Biomarkers Into the Management of Renal Cell Carcinoma - 7:00 - 7:50 PM EST |
|
|
|
|
Role of Radiation in Primary Tumor and Distant Sites in Managing Renal Cell Carcinoma
Presented By: Sophia C. Kamran, MD
|
|
|
|
|
The Emergent Role of Theranostics in Renal Cell Carcinoma
Presented By: Brian M. Shuch, MD
|
|
|
|
|
Update on Biomarkers in Renal Cell Carcinoma
Presented By: David A. Braun, MD, Ph.D.
|
|
|
|
|
|
